# Krazati (adagrasib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/adagrasib

> The FDA approved Krazati (adagrasib), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on December 12, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Krazati (adagrasib) FDA approved?

Yes. The FDA approved Krazati (adagrasib), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on December 12, 2022. FDA novel drug approvals: "Krazati | adagrasib | 12/12/2022 | To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapyDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/adagrasib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/adagrasib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Krazati (adagrasib) |
| Codes | BMS-986503, MRTX849 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | [Solid Tumors](https://sec-api.dev/indications/solid-tumors), Advanced Cancer, [Advanced Non-Small Cell Lung Cancer](https://sec-api.dev/indications/advanced-non-small-cell-lung-cancer), [Carcinoma, Non-Small-Cell Lung](https://sec-api.dev/indications/carcinoma-non-small-cell-lung) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### December 12, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Krazati | adagrasib | 12/12/2022 | To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapyDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "NDA216340 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20221212, review_priority STANDARD; sponsor_name BRISTOL; product KRAZATI (ADAGRASIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216340%22

### June 21, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216340 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240621, review_priority PRIORITY; sponsor_name BRISTOL; product KRAZATI (ADAGRASIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216340%22

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05853575 (Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." https://clinicaltrials.gov/study/NCT05853575

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05853575 (Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-30 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." https://clinicaltrials.gov/study/NCT05853575

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Solid Tumors.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07415031 (A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." https://clinicaltrials.gov/study/NCT07415031

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Solid Tumors.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07415031 (A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." https://clinicaltrials.gov/study/NCT07415031

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04613596 (Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." https://clinicaltrials.gov/study/NCT04613596

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04613596 (Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." https://clinicaltrials.gov/study/NCT04613596

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06875310 (A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." https://clinicaltrials.gov/study/NCT06875310

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06875310 (A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." https://clinicaltrials.gov/study/NCT06875310

## Same indication

- [6-thio-2'-deoxyguanosine](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) (MAIA)
- [Apl-101 oral capsules](https://sec-api.dev/pdufa/apl-101-oral) (APLM)
- [BNT116](https://sec-api.dev/pdufa/bnt116) (REGN)
- [Disitamab vedotin](https://sec-api.dev/pdufa/disitamab-vedotin) (PFE)
- [Domvanalimab](https://sec-api.dev/pdufa/domvanalimab) (RCUS)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [INCB161734](https://sec-api.dev/pdufa/incb161734) (INCY)
- [JNJ-90301900](https://sec-api.dev/pdufa/jnj-90301900) (JNJ)
- [Navlimetostat](https://sec-api.dev/pdufa/navlimetostat) (BMY)
- [Olomorasib](https://sec-api.dev/pdufa/olomorasib) (LLY)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Pembrolizumab/vibostolimab](https://sec-api.dev/pdufa/pembrolizumab-vibostolimab) (MRK)
- [Alimta (pemetrexed)](https://sec-api.dev/pdufa/pemetrexed) (LLY)
- [PF-08634404](https://sec-api.dev/pdufa/pf-08634404) (PFE)
- [AUGTYRO (repotrectinib)](https://sec-api.dev/pdufa/repotrectinib) (BMY)
- [Retevmo (selpercatinib)](https://sec-api.dev/pdufa/selpercatinib) (LLY)
- [Sigvotatug vedotin](https://sec-api.dev/pdufa/sigvotatug-vedotin) (PFE)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [February 2028](https://sec-api.dev/fda-calendar/2028-02), [October 2028](https://sec-api.dev/fda-calendar/2028-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/adagrasib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Krazati (adagrasib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/adagrasib

```bibtex
@misc{secapidev_pdufa_adagrasib_20261116,
  title        = {Krazati (adagrasib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/adagrasib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_adagrasib_20261116","title":"Krazati (adagrasib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/adagrasib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
